Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 5/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.42 |
| ▸ | CDK1 | P06493 | 4/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MGMT | P16455 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15500414 | 0.86 | CDK2 (0.37) | CDK2CCNA2CCNA1CDK1CDK4 | |
| SCHEMBL2686771 | 0.86 | CDK2 (0.37) | CDK2CCNA2CCNA1CDK1CDK4 | |
| SCHEMBL14490772 | 0.73 | CDK2 (0.47) | CDK2CCNA2CCNA1CDK1CDK4 | |
| SCHEMBL13322768 | 0.73 | KMT2A (0.35) | HSP90AB1KMT2AMEN1RXFP1 | |
| SCHEMBL6209356 | 0.72 | CDK2 (0.52) | CDK2CCNA2CCNA1CDK1CDK4 | |
| SCHEMBL4956793 | 0.72 | HSP90AB1 (0.48) | HSP90AB1ABCB1KMT2AMEN1HSP90AA1 | |
| SCHEMBL439475 | 0.72 | CDK2 (0.61) | CDK2CCNA2CCNA1CDK1CDK4 | |
| SCHEMBL3948256 | 0.71 | SMN1; SMN2 (0.45) | KMT2AMEN1KDM4EMAPTPOLB | |
| SCHEMBL9413896 | 0.70 | ABCB1 (0.53) | HSP90AB1ABCB1KMT2AMEN1HSP90AA1 | |
| Hydrochloric Acid SCHEMBL4458130 | 0.70 | HSP90AB1 (0.46) | HSP90AB1ABCB1KMT2AHSP90AA1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4745652-A | DEVELOPERS FOR DYES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1988-05-24 | — | — | US | claimed |
| EP-0256468-A2 | Tetraaminopyrimidine derivatives and their use as hair dyeing agents | Henkel Kommanditgesellschaft auf Aktien (DE) | 1988-02-24 | — | — | EP | claimed |
| US-20170065592-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. | 2017-03-09 | — | — | US | disclosed |
| US-7501513-B2 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2009-03-10 | — | — | US | disclosed |
| EP-1658081-B1 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA IP NV (BE) | 2007-10-24 | — | — | EP | disclosed |
| US-7276506-B2 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2007-10-02 | — | — | US | disclosed |
| EP-1673092-B1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| EP-1673092-B1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| EP-1663244-B1 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF TNF-ALPHA-RELATED DISEASES. | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| EP-1663244-B1 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF TNF-ALPHA-RELATED DISEASES. | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | 4 AZA BIOSCIENCE NV (BE) | 2007-02-08 | — | — | US | disclosed |
| WO-2005039587-A1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA BIOSCIENCE NV (BE) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005025574-A2 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-α-RELATED DISEASES. | 4 AZA BIOSCIENCE NV (BE) | 2005-03-24 | — | — | WO | disclosed |
| US-5500428-A | Furyl-substituted purines and adenosine antagonists | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1996-03-19 | — | — | US | disclosed |
| US-5300509-A | Adenosine antagonists for treating cardiovascular disorders, vasodilation | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-04-05 | — | — | US | disclosed |
| EP-0584797-A2 | Novel cephalosporin compounds and processes for the preparation thereof | LUCKY LTD. (KR) | 1994-03-02 | — | — | EP | disclosed |
| EP-0544445-A2 | Furyl-substituted purines, oxazolopyrimidines and pteridines as adenosine antagonists | ZENECA LIMITED (GB) | 1993-06-02 | — | — | EP | disclosed |
| US-4745652-A | DEVELOPERS FOR DYES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1988-05-24 | — | — | US | disclosed |
| EP-0256468-A2 | Tetraaminopyrimidine derivatives and their use as hair dyeing agents | Henkel Kommanditgesellschaft auf Aktien (DE) | 1988-02-24 | — | — | EP | disclosed |
| US-4286093-A | 9-Cyclohexyl-2-alkoxy-9H-adenine process | MEAD JOHNSON & COMPANY (US) | 1981-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | TPMT, TYMS, TNF | CDK2 723/4885CCNA2 1271/4885CCNA1 629/4885 |
| US-20170065592-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR2, TLR6 | CDK2 4091/4885CCNA2 4384/4885CCNA1 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.